Trial Profile
A Phase I, Open-Label, Dose-Escalation Trial With BI 836826 in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma of B Cell Origin
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 12 Aug 2020
Price :
$35
*
At a glance
- Drugs BI 836826 (Primary)
- Indications B-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 14 Mar 2020 Results assessing the maximum tolerated dose (MTD), safety, and efficacy of BI 836826 in patients with relapsed or refractory B cell NHL published in the Investigational New Drugs
- 07 Mar 2018 Status changed from active, no longer recruiting to completed.
- 22 Dec 2017 Status changed from recruiting to active, no longer recruiting.